Pieris Pharmaceuticals (PIRS) & EXACT Sciences (EXAS) Head-To-Head Comparison

Share on StockTwits

Pieris Pharmaceuticals (NASDAQ: EXAS) and EXACT Sciences (NASDAQ:EXAS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider & Institutional Ownership

64.9% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.4% of EXACT Sciences shares are owned by institutional investors. 5.1% of Pieris Pharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of EXACT Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Pieris Pharmaceuticals and EXACT Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pieris Pharmaceuticals $25.27 million 11.27 -$17.64 million ($0.40) -13.18
EXACT Sciences $265.99 million 35.64 -$114.39 million ($0.99) -78.00

Pieris Pharmaceuticals has higher earnings, but lower revenue than EXACT Sciences. EXACT Sciences is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Pieris Pharmaceuticals and EXACT Sciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 5 0 3.00
EXACT Sciences 0 2 9 0 2.82

Pieris Pharmaceuticals presently has a consensus target price of $12.33, indicating a potential upside of 134.03%. EXACT Sciences has a consensus target price of $80.40, indicating a potential upside of 4.12%. Given Pieris Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Pieris Pharmaceuticals is more favorable than EXACT Sciences.

Risk and Volatility

Pieris Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, EXACT Sciences has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Profitability

This table compares Pieris Pharmaceuticals and EXACT Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -22.38% -27.81% -6.31%
EXACT Sciences -35.24% -20.10% -12.69%

Summary

Pieris Pharmaceuticals beats EXACT Sciences on 9 of the 14 factors compared between the two stocks.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply